Program
DA-2811
A development code. Also written as “DA-2811-C” and “DA-2811-R”.
Its studies are mostly in Diabetes Mellitus, led by Dong-A ST.
Furthest: phase 4, since Feb 15, 20234 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Dong-A ST | 41 open or running | phase 4since Feb 15, 2023 | Jul 13, 2020 | Dec 2026phase 2 · NCT07239440 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 13, 2020First study: phase 1 study in HealthyFirst studyNCT04473417 · 60 enrolled · Korea, Republic of
- Jun 16, 2021Phase 1 study in HealthyNCT04938752 · 30 enrolled · Korea, Republic of
- Feb 15, 2023Phase 4 study in Diabetes MellitusNCT05743907 · 231 enrolled · Korea, Republic of
- Nov 16, 2025Phase 2 study in Diabetes MellitusNCT07239440 · 288 planned · South Korea
Ahead
- Dec 2026Primary completion: phase 2 study in Diabetes MellitusNCT07239440
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07239440Diabetes Mellitus · South Korea | 2 | Not yet recruiting | Dec 2026 | 288 |
| NCT05743907Diabetes Mellitus · Korea, Republic of | 4 | Completed | Mar 10, 2025 | 231 |
| NCT04938752Healthy · Korea, Republic of | 1 | Completed | Aug 20, 2021 | 30 |
| NCT04473417Healthy · Korea, Republic of | 1 | Completed | Aug 26, 2020 | 60 |
How it is read
Names in the registry
- “DA-2811”, 6 entries
- “DA-2811-C”, 1 entry
- “DA-2811-R”, 1 entry
Codes read as this program: DA2811.
Conditions, from the studies’ own filings
- Diabetes Mellitus, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.